Publication information: “Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity,” from Cell Reports Medicine ...

Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the United States patent office covering proprietary manufacturing technology for its novel vaccination ...

Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the United States patent office covering proprietary manufacturing technology for its novel ...

Since the onset of the COVID-19 pandemic, vaccination rates for both children and adults have declined. Public trust in ...

Public health physician Dr. Marcy Ahun discusses vaccine delivery innovations, like the auto-disable syringe, that have prevented needle reuse and saved lives in the process.

Whether finding new treatments for schizophrenia or first-time ways to tackle bladder cancer, these companies are finding ...

Philip Bergman, DVM, MS, PhD, DACVIM (Oncology), kicked off the 2025 Fetch Charlotte conference with his keynote address on ...

WASHINGTON – There sat Robert F. Kennedy Jr., the nation’s top health official, at a Steak ’n Shake with Fox News host Sean ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...

Klein and Thompson have produced an eminently rational and readable analysis of America’s policy morass in their book ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

“A simple way to describe this to the average person is the serious adverse events generally occur at a rate of 1 to a few cases per million doses of vaccine,” he said. “That’s a needle in ...